Dimensional Fund Advisors’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.2M Buy
951,589
+853,515
+870% +$14.7M ﹤0.01% 2038
2025
Q4
$1.92M Buy
+98,074
New +$1.86M ﹤0.01% 2747
2025
Q2
Sell
-12,569
Closed -$131K 3287
2025
Q1
$131K Sell
12,569
-87,009
-87% -$1.24M ﹤0.01% 3172
2024
Q4
$2.35M Sell
99,578
-66,569
-40% -$1.97M ﹤0.01% 2747
2024
Q3
$5.96M Sell
166,147
-5,038
-3% -$201K ﹤0.01% 2478
2024
Q2
$6.04M Sell
171,185
-155,444
-48% -$4.52M ﹤0.01% 2429
2024
Q1
$9.27M Sell
326,629
-478,922
-59% -$10.8M ﹤0.01% 2338
2023
Q4
$10.7M Sell
805,551
-137,657
-15% -$1.34M ﹤0.01% 2296
2023
Q3
$8.45M Buy
943,208
+142,983
+18% +$1.54M ﹤0.01% 2344
2023
Q2
$9M Buy
800,225
+139,595
+21% +$1.65M ﹤0.01% 2306
2023
Q1
$7.61M Buy
660,630
+204,642
+45% +$2.66M ﹤0.01% 2336
2022
Q4
$5.28K Buy
455,988
+168,387
+59% +$1.95M ﹤0.01% 2432
2022
Q3
$3.65M Buy
287,601
+204,811
+247% +$2.35M ﹤0.01% 2527
2022
Q2
$568K Buy
82,790
+32,512
+65% +$224K ﹤0.01% 3036
2022
Q1
$484K Buy
50,278
+14,266
+40% +$121K ﹤0.01% 3159
2021
Q4
$428K Buy
+36,012
New +$506K ﹤0.01% 3201

Other funds holding DYN

Dimensional Fund Advisors's DYN Position: Q1 2026 in Review

Dimensional Fund Advisors increased its Dyne Therapeutics (DYN) stake by 870% in Q1 2026, buying an estimated $14.7M and bringing the position to 951,589 shares worth $17.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2038.

Dimensional Fund Advisors first reported a position in DYN in Q4 2021 and has held it in 16 quarters since. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • Dimensional Fund Advisors held 951,589 shares of Dyne Therapeutics worth $17.2M as of Q1 2026.
  • Dimensional Fund Advisors bought 853,515 Dyne Therapeutics shares in Q1 2026, an estimated $14.7M.
  • Dyne Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q1 2026, its #2038 holding.
  • Dimensional Fund Advisors first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Dimensional Fund Advisors's 13F filing for Q1 2026, filed 7 May 2026.